9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 55

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: Response Assessment,  Count of Participants With SS1P Antibody Formation,  Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) Who Were Administered SS1P and Pentostatin or Cyclophosphamide, Recommended Phase 2 Dose (RP2D) in Drug Lot FIL129J01

Interventions: Pentostatin, Cyclophosphamide

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: August 3, 2016

Completion Date: August 7, 2017

Last  Posted Date: June 6, 2019

Location: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT01362790

Was this article helpful?
Dislike 0